Catharine Mans Bosio, Ph.D., B.Sc.
Immunity to Pulmonary Pathogens Sections
Rocky Mountain Laboratories
Building 28, Room 1A126
903 South 4th Street
Hamilton, MT 59840
The focus of our research is to gain a better understanding of how aerosolized pathogens successfully infect and modulate the pulmonary environment to cause overt disease and death. Currently, our principal interest is the pathogenesis of aerosolized F. tularensis, the causative agent of pneumonic tularemia.
There are two primary areas of research ongoing in our laboratory: innate immunity to F. tularensis, and modulation of human cells by F. tularensis. We are particularly interested in modulation of primary antigen-presenting cells (dendritic cells and macrophages) by F. tularensis and how this modulation allows the bacterium to initially evade host immune responses immediately following infection. We utilize both in vivo and in vitro models of disease to reveal specific mechanisms at play in both host and pathogen to gain a better understanding of the dynamic nature of this disease.
Dr. Bosio graduated from Washington State University cum laude with a B.Sc. in 1993. Following completion of her Ph.D. at Colorado State University in 1998, Dr. Bosio completed postdoctoral fellowships at the Food and Drug Administration Center for Biologics Evaluation and Research and at the U.S. Army Medical Research Institute for Infectious Diseases, studying innate immunity to Mycobacterium tuberculosis, F. tularensis, Marburg virus, and Ebola virus. Prior to joining NIAID in 2007, Dr. Bosio was an assistant professor at Colorado State University in the department of microbiology, immunology, and pathology. Dr. Bosio’s laboratory studies the host response to pulmonary pathogens, with special emphasis on virulent F. tularensis and dendritic cells, macrophages, and monocytes.
Roberts LM, Crane DD, Wehrly TD, Fletcher JR, Jones BD, Bosio CM. Inclusion of Epitopes That Expand High-Avidity CD4+ T Cells Transforms Subprotective Vaccines to Efficacious Immunogens against Virulent Francisella tularensis. J Immunol. 2016;197(7):2738-47.
Wyatt EV, Diaz K, Griffin AJ, Rasmussen JA, Crane DD, Jones BD, Bosio CM. Metabolic Reprogramming of Host Cells by Virulent Francisella tularensis for Optimal Replication and Modulation of Inflammation. J Immunol. 2016;196(10):4227-36.
Crane DD, Ireland R, Alinger JB, Small P, Bosio CM. Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor α. Clin Vaccine Immunol. 2013;20(10):1531-40.
Ireland R, Wang R, Alinger JB, Small P, Bosio CM. Francisella tularensis SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8. J Immunol. 2013;191(3):1276-86.
Related Scientific Focus Areas
Microbiology and Infectious Diseases
This page was last updated on April 24th, 2018